Hemostemix Closes $2,969,600 Private Placement

Core Points - Hemostemix Inc has completed a non-brokered private placement, raising gross proceeds of $2,969,600 from the sale of 29,696,000 units at a price of $0.10 per unit [1][2] - Each unit consists of one common share and one common share purchase warrant, with the warrants exercisable at $0.15 for two years, subject to an acceleration clause [2] - The proceeds will be used for the repayment of a debt at a 50% discount and for general working capital to support operational expenses, including marketing of VesCell™ [4] Financial Details - The company paid approximately $97,600 in cash finder fees and issued 976,000 finder's options at an exercise price of $0.15 [3] - The offering is classified as a related party transaction, with directors participating, and the company will file a material change report as required [5] Shareholder Information - Prior to the offering, Mr. Peter Lacey owned 9,316,937 common shares, representing 6.14% on a partially diluted basis; after subscribing to 15,000,000 units, he now owns 24,316,937 shares, equating to 13.40% on a non-diluted basis [6] Stock Options - The company granted 3,870,000 stock options to directors, officers, employees, and consultants at an exercise price of $0.13, expiring on July 23, 2030 [9] - After this issuance, the total outstanding options amount to 18,111,694 [9] Company Overview - Hemostemix is an autologous stem cell therapy platform company, recognized for its patented VesCell™ therapy, which has shown promising results in clinical studies for various cardiovascular conditions [10]